Ei­sai heads to FDA with sub­cu­ta­neous ver­sion of Alzheimer’s treat­ment de­vel­oped with Bio­gen

Ei­sai and Bio­gen said Tues­day that they start­ed an ap­pli­ca­tion for an un­der-the-skin main­te­nance dos­ing ver­sion of their Alzheimer’s treat­ment Leqem­bi.

The sub­cu­ta­neous sub­mis­sion was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.